NantHealth (NASDAQ:NH) will be issuing its quarterly earnings data after the market closes on Wednesday, March 14th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.
Shares of NantHealth (NH) opened at $3.67 on Monday. NantHealth has a fifty-two week low of $2.60 and a fifty-two week high of $6.43. The company has a market cap of $397.57, a price-to-earnings ratio of -2.06 and a beta of 0.64. The company has a current ratio of 2.38, a quick ratio of 2.36 and a debt-to-equity ratio of 0.93.
In other news, COO Ronald Allen Louks sold 7,095 shares of NantHealth stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $3.56, for a total value of $25,258.20. Following the completion of the transaction, the chief operating officer now owns 89,690 shares of the company’s stock, valued at approximately $319,296.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 19,745 shares of company stock valued at $66,549. 58.00% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of NH. Vanguard Group Inc. raised its position in NantHealth by 20.2% in the 2nd quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock worth $1,792,000 after buying an additional 71,087 shares during the last quarter. Northern Trust Corp raised its position in NantHealth by 133.9% in the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock worth $643,000 after buying an additional 86,955 shares during the last quarter. State Street Corp raised its position in NantHealth by 88.1% in the 2nd quarter. State Street Corp now owns 147,234 shares of the company’s stock worth $623,000 after buying an additional 68,963 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in NantHealth by 132.4% in the 2nd quarter. California State Teachers Retirement System now owns 31,600 shares of the company’s stock worth $134,000 after buying an additional 18,000 shares during the last quarter. 6.27% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have recently issued reports on the company. BidaskClub lowered NantHealth from a “hold” rating to a “sell” rating in a research report on Friday, January 26th. Zacks Investment Research raised NantHealth from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research report on Thursday, December 21st. Finally, Canaccord Genuity lowered their price target on NantHealth from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, November 17th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. NantHealth has a consensus rating of “Buy” and a consensus price target of $8.05.
TRADEMARK VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/12/nanthealth-nh-to-release-earnings-on-wednesday.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.